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Abstract
Background: The genetic contribution to the aetiology of anti-neutrophil cytoplasmic antibody
(ANCA)-associated vasculitis (AAV) is not well defined. Across different autoimmune diseases
some genes with immunomodulatory roles, such as PTPN22, are frequently associated with multiple
diseases, whereas specific HLA associations, such as HLA-B27, tend to be disease restricted. We
studied ten candidate loci on the basis of their immunoregulatory role and prior associations with
type 1 diabetes (T1D). These included PTPN22, CTLA4 and CD226, which have previously been
associated with AAV.
Methods: We genotyped the following 11 SNPs, from 10 loci, in 641 AAV patients using TaqMan
genotyping: rs2476601 in PTPN22, rs1990760 in IFIH1, rs3087243 in CTLA4, rs2069763 in IL2,
rs10877012 in CYP27B1, rs2292239 in ERBB3, rs3184504 in SH2B3, rs12708716 in CLEC16A,
rs1893217 and rs478582 in PTPN2 and rs763361 in CD226. Where possible, we performed a meta-
analysis with previous analyses.
Results: Both CTLA4 rs3087243 and PTPN22 rs2476601 showed association with AAV, P = 6.4 ×
10-3 and P = 1.4 × 10-4 respectively. The minor allele (A) of CTLA4 rs3087243 is protective (odds
ratio = 0.84), whereas the minor allele (A) of PTPN22 rs2476601 confers susceptibility (odds ratio
= 1.40). These results confirmed previously described associations with AAV. After meta-analysis,
the PTPN22 rs2476601 association was further strengthened (combined P = 4.2 × 10-7, odds ratio
of 1.48 for the A allele). The other 9 SNPs, including rs763361 in CD226, showed no association
with AAV.
Conclusion: Our study of T1D associated SNPs in AAV has confirmed CTLA4 and PTPN22 as
susceptibility loci in AAV. These genes encode two key regulators of the immune response and are
Published: 1 December 2009
BMC Medical Genetics 2009, 10:121 doi:10.1186/1471-2350-10-121
Received: 28 July 2009
Accepted: 1 December 2009
This article is available from: http://www.biomedcentral.com/1471-2350/10/121
© 2009 Carr et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2009, 10:121 http://www.biomedcentral.com/1471-2350/10/121
Page 2 of 7
(page number not for citation purposes)
associated with many autoimmune diseases, including T1D, autoimmune thyroid disease, celiac
disease, rheumatoid arthritis, and now AAV.
Background
Anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is characterised by small vessel inflamma-
tion and necrosis, and autoantibodies against specific
neutrophil components (ANCA). The anatomical context
of the inflamed vessels determines the signs and symp-
toms of disease. Renal and lung manifestations are com-
mon but any organ or system can be affected. AAV
includes the clinical syndromes Wegener's granulomato-
sis (WG), microscopic polyangiitis (MPA) and Churg-
Strauss Syndrome (CSS). AAV is a complex disease with
both genetic and environmental factors involved in
pathogenesis [1]. The magnitude of the increased familial
risk is moderate; it is lower than that seen in systemic
lupus erythematosus (SLE) or multiple sclerosis, but sim-
ilar to that observed in rheumatoid arthritis [2]. The genes
responsible for most of this risk are unknown [3]. The
only consistent HLA association is with DPB1*0401 [4],
however many HLA class I and class II molecules have
been associated with disease in small non-replicated stud-
ies [3].
There is increasing evidence that susceptibility loci are
shared between autoimmune diseases [5]. Therefore, we
tested ten candidate loci on the basis of prior replicated
associations with T1D [6,7]. The candidate loci tested
were  PTPN22,  IFIH1,  CTLA4,  IL2,  CYP27B1,  ERBB3,
SH2B3,  CLEC16A,  PTPN2  and  CD226. We have previ-
ously reported an association between IL2RA and AAV [8].
Prior evidence supporting association exists for CTLA4,
PTPN22 and CD226 [9-12]. CTLA-4 protein expression on
CD4 T cells is increased in WG [13]. Several studies tested
CTLA4 for association with WG or AAV. The results of
these studies are conflicting. Giscombe et al. found an
association with a SNP at position -318 (rs5742909)
using 32 WG patients and 122 controls [9]. Zhou et al.
found an association between WG and shorter (AT)n mic-
rosatellite length in the 3'UTR of CTLA4 in a cohort of 117
WG patients and 123 controls [14]. Slot et al. reported an
association with a different SNP at position +49 using 102
AAV patients and 192 controls, and no effect at position -
318 or the (AT)n microsatellite [10]. Finally, Spriewald et
al. reported no association with either of the SNPs -318 or
+49, or the (AT)n microsatellite in the 3'UTR of CTLA4,
using 32 WG patients and 91 controls [15]. The prior
PTPN22 report used 199 WG cases and 399 healthy con-
trols and rs2476601 [11]. The CD226 report used 642
German WG patients and 1226 controls, but, in a parallel
analysis, did not find an association in a cohort of 105 UK
WG patients [12]. We sought to confirm these prior asso-
ciations, and test the other T1D susceptibility loci, using a
collection of 641 AAV cases and 9115 controls.
Methods
Patients and controls
The AAV cohort comprises subjects from four sources, all
meeting the Chapel Hill diagnostic criteria [16]:
1. The MRC/Kidney Research UK (KRUK) National
DNA Bank for Glomerulonephritis. Individuals were
between the ages of 18 and 70 years, were ANCA sero-
positive, and had biopsy-proven necrotizing glomeru-
lonephritis.
2. The UK vasculitis cohort 2 was recruited from 9 cen-
tres in the UK and comprised patients seropositive for
ANCA and/or with histological evidence of small ves-
sel vasculitis.
3. Patients recruited from the University of Birming-
ham. All individuals were ANCA seropositive with
firm clinical and/or histological evidence of vasculitis.
4. The Lupus and Vasculitis Service, Addenbrooke's
Hospital, Cambridge. All individuals were ANCA sero-
positive with firm clinical and/or histological evidence
of vasculitis.
Genotyping was performed using TaqMan genotyping kits
(Applied Biosystems) for each SNP, with fluorescence
data captured using an ABI 7900 HT Fast Real-Time PCR
System (Applied Biosystems) after 40 cycles of PCR.
Control genotypes for 9115 individuals from the British
1958 Birth Cohort and UK Blood Service were obtained
from the Juvenile Diabetes Research Foundation/Well-
come Trust Diabetes and Inflammation Laboratory [6].
This cohort is an expansion of a dataset previously shown
to be appropriate for use as UK-wide controls [17]. The
1958 Birth Cohort DNA was collected as part of an ongo-
ing study following all births in England, Scotland and
Wales in one week in 1958 http://
www.b58cgene.sgul.ac.uk. This study was approved by
the Cambridge Local Research Ethics Committee and by
the Oversight Committee of the KRUK DNA Bank.
Statistical analysis
Statistical analysis was performed using Prism (Graph-
Pad) and R http://www.r-project.org. Genotype tests were
performed using χ2 tests for significance on 3 × 2 contin-BMC Medical Genetics 2009, 10:121 http://www.biomedcentral.com/1471-2350/10/121
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gency tables. Allele analyses were performed using χ2 tests
for significance on 2 × 2 contingency tables. Odds ratios
and 95% confidence intervals were calculated from the
same 2 × 2 tables. One-sided, log-additive power calcula-
tions were performed using Quanto 1.2.4 http://
hydra.usc.edu/gxe/, and the determined allele frequencies
and effect sizes. Co-dominant, dominant, over-dominant,
recessive and log-additive modelling was performed using
the R package SNPassoc [18]. The SNPs genotyped are not
within the thirteen genomic loci identified by the Well-
come Trust Case Control Consortium as showing geno-
type variation by geographic region of the UK [17], and it
was therefore not necessary to stratify these analyses by
geographical location.
Results
In this AAV association study, eight of the ten regions
tested did not show an AAV association, with P values
between 0.19 and 0.75 (table 1). Genotypes for all SNPs
did not significantly deviate from Hardy-Weinberg equi-
librium in either cases or controls.
Two loci, CTLA4 and PTPN22, marked by rs3087243 and
rs2476601 respectively, were associated with disease
(tables 1 &2). rs3087243 in CTLA4 was associated with
disease using both genotype and allele tests (allelic P = 6.4
× 10-3; table 2). The minor allele (A) at this locus was pro-
tective, with an odds ratio (OR) of 0.84 (95% confidence
interval 0.75 - 0.95). We also found both genotype and
allelic associations between rs2476601 in PTPN22  and
AAV (allelic P = 1.4 × 10-4; table 2). The minor allele (A)
of rs2476601 confers susceptibility with an OR of 1.40
(95% confidence interval 1.18 - 1.67).
There is a prior study reporting an association between
PTPN22 rs2476601 and Wegener's granulomatosis [11].
The results of our meta-analysis (table 3), demonstrate a
validated association for PTPN22 and AAV (allelic P = 4.2
× 10-7). In both PTPN22 studies the minor allele conferred
susceptibility. The combined odds ratio for the minor
allele is 1.48 (95% confidence interval 1.27 - 1.71). For a
subset of our AAV patients, WG and MPA diagnoses were
available. The effect of rs2476601 is present in both WG
and MPA compared with the same control population
(WG: n = 205, allelic P = 6 × 10-11, OR = 2.01; MPA: n =
74, allelic P = 4.1 × 10-6, OR = 2.55).
The prior CTLA4 studies with positive results used SNPs at
positions -318 and +49, rather than rs3087243, preclud-
ing a meta-analysis [9,10]. We also tested for differential
associations in WG or MPA but were unable to demon-
strate an association with either of our smaller WG or
MPA cohorts alone (data not shown).
The prior CD226  study reported an association with
rs763361 in a cohort of German patients, but did not find
an association in a collection from the University of Bir-
mingham [12]. We also find no association between
Table 1: Allele association testing in AAV of 11 SNPs at 10 loci
Chr Gene SNP Controls
n = 9115
Vasculitis cases
n = 641
MAF MAF P value OR (95% CI)
1p13 PTPN22 rs2476601 G>A (R620W) 0.10 0.13 1.4 × 10-4 1.40
(1.18 - 1.67)
2q24 IFIH1 rs1990760 T>C (A946T) 0.39 0.40 0.47 1.05
(0.93 - 1.18)
2q33 CTLA4 rs3087243 G>A 0.45 0.41 6.4 × 10-3 0.84
(0.75 - 0.95)
4q27 IL2 rs2069763 G>T 0.32 0.31 0.51 0.95
(0.82 - 1.10)
12q13 CYP27B1 rs10877012 G>T 0.33 0.32 0.34 0.93
(0.82 - 1.07)
12q13 ERBB3 rs2292239 A>C 0.35 0.35 0.75 0.97
(0.86 - 1.11)
12q24 SH2B3 rs3184504 C>T (R292W) 0.48 0.49 0.56 1.04
(0.92 - 1.17)
16p13 CLEC16A rs12708716 A>G 0.35 0.36 0.24 1.08
(0.95 - 1.22)
18p11 PTPN2 rs1893217 T>C 0.17 0.19 0.19 1.12
(0.95 - 1.31)
18p11 PTPN2 rs478582
T>C
0.45 0.43 0.26 0.93
(0.83 - 1.05)
18q22 CD226 rs763361
C>T (G307S)
0.49 0.47 0.21 0.90
(0.77 - 1.06)
Chromosome is abbreviated to Chr; minor allele frequency is MAF; odds ratio is OR and confidence interval is CI.BMC Medical Genetics 2009, 10:121 http://www.biomedcentral.com/1471-2350/10/121
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CD226 and AAV patients from the United Kingdom (P =
0.21, table 1). Excluding AAV patients from the University
of Birmingham from our cohort, to minimise any poten-
tial confounding effects, does not alter the analysis (n =
391, allelic P = 0.38, OR = 0.93, 95% CI = 0.78 - 1.10,
power = 27.3%).
For both CTLA4 rs3087243 and PTPN22 rs2476601, we
tested the genotype data (table 2) using several different
models of inheritance (co-dominant, dominant, over-
dominant, recessive and log-additive). No single model
had a clearly superior fit at either locus (table 4).
Discussion
CTLA4 and PTPN22 are now firmly established as AAV
susceptibility loci, along with HLA-DPB, with associations
confirmed in two separate cohorts. Clarification of the
potentially complex role of the CTLA4 locus in AAV, as
implied by apparently conflicting prior studies
[9,10,14,15], would be provided by a larger, more
detailed study of the locus. PTRN3 and AAT are the only
other confirmed AAV associations [1].
CTLA4 encodes cytotoxic T lymphocyte antigen 4 (CTLA-
4), a negative regulator of T cell activation. Ctla4-/- mice
die by 3-4 weeks of age, with lymphadenopathy and
splenomegaly, consisting of T cell expansions expressing
activation markers [19], and lymphocytic infiltration and
tissue destruction of many organs, including heart and
pancreas [20]. Numerous subsequent studies have
revealed that CTLA-4 has complex biology; it is known to
bind CD80 and CD86 with higher affinity than CD28
Table 2: Genotype and allele associations for CTLA4 rs3087243 and PTPN22 rs2476601 in AAV
Controls AAV cases
n Frequency n Frequency P value
CTLA4 rs3087243
GG 2726 0.30 198 0.34
GA 4453 0.49 282 0.49
AA 1861 0.21 95 0.17 0.02*
G 9905 0.55 678 0.59
A 8175 0.45 472 0.41 6.4 × 10-3 ** §
PTPN22 rs2476601
GG 6044 0.82 471 0.75
GA 1298 0.18 146 0.23
AA 70 0.01 9 0.01 5.2 × 10-4 *
G 13386 0.90 1088 0.87
A 1438 0.10 164 0.13 1.4 × 10-4 **§§
* P value calculated by χ2 test on 3 × 2 contingency table
** P value calculated by χ2 test on 2 × 2 contingency table
§ Odds ratio (OR) for minor allele (A) = 0.84
§§ OR for minor allele = 1.40
Table 3: Meta-analysis for PTPN22 rs2476601 in AAV
Controls 
this study//Jagiello1
AAV cases 
this study//Jagiello1
n
7412//399
Frequency n
626//199
Frequency Combined
P value
GG 6044//323 0.82//0.81 471//142 0.75//0.71
GA 1298//72 0.18//0.18 146//52 0.23//0.26
AA 70//4 0.01//0.01 9//5 0.01//0.03 2.2 × 10-6 *
G 13386//718 0.90//0.90 1088//336 0.86//0.84
A 1438//80 0.10//0.10 164//62 0.13//0.16 4.2 × 10-7 ** §
1 Data from Jagiello et al [11]
* P value calculated by χ2 test on 3 × 2 contingency table
** P value calculated by χ2 test on 2 × 2 contingency table
§ OR for minor allele = 1.48BMC Medical Genetics 2009, 10:121 http://www.biomedcentral.com/1471-2350/10/121
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[21,22], it is expressed by both regulatory and effector T
cells, and it is synthesised as soluble and transmembrane
isoforms [23] with the majority of CTLA-4 retained intra-
cellularly. Specific deficiency of Ctla4-/-  in natural
Foxp3+CD4+ regulatory T cells results in spontaneous
autoimmune disease [24]. The precise role of CTLA-4 in
the maintenance of peripheral tolerance remains unclear,
with no unifying model of CTLA-4 function [25]. Human
polymorphisms in CTLA4  are associated with several
autoimmune diseases, including type 1 diabetes (T1D),
Graves' disease [6,26], Hashimoto's thyroiditis [27], celiac
disease [28], and rheumatoid arthritis (RA) [29].
CD4 T cells from AAV patients express higher levels of
membrane-bound CTLA-4 protein than CD4 T cells from
healthy controls [13]. The common G allele of rs3087243,
which confers susceptibility to AAV, does not alter expres-
sion of full length CTLA4 mRNA [26]. Despite the G allele
of rs3087243 associating with a lowered expression of the
CTLA4 transcript encoding the soluble form of the protein
[26], genotype at rs3087243 does not correlate with solu-
ble CTLA-4 protein in serum from T1D patients or from
autoantibody positive or negative healthy controls [30]. A
different SNP, rs5742909, in the CTLA4 promoter region
may be associated with expression level [31] and there is
some evidence of association with WG [9]. Linkage dise-
quilibrium between rs3087243 and rs5742909 is low (r2
= 0.074; CEPH dataset, http://hapmap.ncbi.nlm.nih.gov/
. Thus rs57942909 may have an independent effect to that
conferred by rs3087243.
In addition to the effects on the expression of CTLA4 iso-
forms, the two alleles of rs3087243 are associated with
altered T cell phosphorylation levels [32]. CD4 T cells
from carriers of the AAV risk-conferring G allele exhibit
greater levels of phospho-LAT, phospho-LCK, phospho-
ZAP70, and phospho-SLP76 after anti-CD3 treatment.
There have been no reported differences in CTLA-4 pro-
tein expression on CD4 T cells between donors of all
rs3087243 genotypes. The lower activation threshold of T
cells from carriers of the G allele of rs3087243 might thus
contribute to T cell activation and autoimmune disease
susceptibility. Taken together these data suggest that gen-
otype at rs3087243 could impact upon both the expres-
sion of CTLA4 mRNA isoforms and the subsequent level
and function of the translated protein.
PTPN22 encodes a second negative regulator of T cell acti-
vation, LYP. The SNP rs2476601 is a non-synonymous
change substituting arginine for tryptophan at amino acid
residue 620. PTPN22 is being increasingly recognised as a
central player in T cell regulation, being a direct target for
inhibition by the regulatory T cell transcription factor
Foxp3 [33] and by the T cell modulating mir-181a [34].
The predisposing allele in T1D, RA and AAV is Trp620 (the
A allele). T cell receptor stimulation of T cells from carriers
of the Trp620 allele, resulted in decreased interleukin 2
production due to increased phosphatase activity [35].
The functional implications of this SNP also extend to B
cells, where the Trp620 allele reduces activation thresholds
in an analogous manner to T cells, perhaps allowing
autoantibody production by B cells in addition to the
effects of the Trp620 allele in T cells [36]. However, whilst
mice lacking Pep (the murine ortholog of PTPN22) have
spontaneous germinal centre formation, autoantibodies
have not been described [37]. While the Trp620 PTPN22
allele is associated with susceptibility in many diseases
[38], the alternative Arg620 allele confers risk in others
(such as Crohn's disease [39]). This underlines the impor-
tance of the pathway controlled by PTPN22 in autoimmu-
nity, but indicates distinct regulatory changes in the
pathway are involved in different disease states. It has
been suggested that the Trp620  allele is implicated in
autoimmune diseases associated with autoantibody pro-
duction, such as AAV or T1D [36], and indeed the Trp620
allele of rs2476601 in PTPN22 is associated with both WG
and MPA.
CTLA4, PTPN22 and IL2RA are all genes associated with
the regulation of T cell activation, via the modulation of
signalling in effector T cells and the control of regulatory
T cells. All of these genes are associated with multiple
autoimmune diseases, including T1D, autoimmune thy-
roid disease and AAV [6,8,26,40-42]. This may in part
explain the familial co-segregation seen between some of
these diseases, for example between T1D and autoim-
mune thyroid disease [26,43]. AAV however does not
show clear evidence for co-segregation with other autoim-
mune diseases, implying the existence of susceptibility
loci unique to AAV pathogenesis. These unique loci, by
their nature, are difficult to identify with candidate gene
studies, demonstrating the need for a genome-wide asso-
ciation study in AAV.
Table 4: Models of inheritance for the CTLA4 rs3087243 and PTPN22 rs2476601 associations in AAV
P value of indicated model
Co-dominant Dominant Over-dominant Recessive Log-additive
CTLA4
rs3087243
0.02 0.03 0.92 0.02 5.8 × 10-3
PTPN22
rs2476601
8.5 × 10-4 1.8 × 10-4 4.3 × 10-4 0.26 2.0 × 10-4BMC Medical Genetics 2009, 10:121 http://www.biomedcentral.com/1471-2350/10/121
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Conclusion
We confirm two associations with AAV in CTLA4  and
PTPN22, both important regulators of the immune
response. There are now five confirmed AAV susceptibility
loci: HLA-DPB1, CTLA4, PTPN22, PRTN3 and AAT.
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